Get started

Healthcarestocks

Regeneron Pharmaceuticals | REGN | Long at $502.28Regeneron Pharmaceuticals NASDAQ:REGN stock dropped more than 17% today due to mixed Phase 3 trial results for itepekimab, a potential COPD drug. However, the company has an extensive drug pipeline, raked in over $14 billion last year, and is currently trading at a price-to-earnings of 15x. Debt-to-equity is 0.09x (extremely healthy) and earnings are forecast to grow 7.5% per year. While 2025 is anticipated to be its "worst" earnings year, the outlook through 2028 looks like steady growth in revenue and cash flow. From a technical analysis view, the stocks entered my "crash" simple moving average zone today (currently between $466 and $502). More often than not, this area signals a bottom in the near-term, but it's not guaranteed. I wouldn't be surprised if the $450s-$460s get hit before a reversal if the market shifts negatively - which will be another entry for me. If it moves into my "major" crash zone in the $300s to close more gaps on the daily chart, I will be piling into this stock heavily (like I did with NYSE:UNH ) for a longer-term hold - of course, unless fundamentals change. I'm going to keep my target small unless there is a "major crash" and eye the closing of the nearest price gap on the daily. There is another between $883-$914... Targets: $590 (+17.5%)
NASDAQ:REGNLong
by WorthlessViews
1
LLY - Clean Levels UpdatedEli Lilly's hit those 708.49 and 711 levels I mentioned in my previous LLY post. I've added some weekly levels, and a couple relevant spots from my boxed LLY chart. If LLY loses steam up here we could easily see a retest of that box top area in the $680 - $678 range. Otherwise if we see a market wide reversion from today's liquidation, and LLY clears today's high(~714) and firmly holds that high volume area, that gap($738) fill would be a no-brainer. Personally leaning on the side of a short continuation(in the near time at least), didn't really trust the low volume float up over the last few trading days, and definitely don't like the decreasing volume into that $711 - $714 area (I'd consider it a Look above and fail). Regardless of bias, we trade what we see. ~ The Villain.
NYSE:LLYShort
by The_Villain_777
CVS Breaking out Longterm?NYSE:CVS will be pulling Aetna out of the ACA Exchange Business in 2026. the Exchange has caused significant losses for the company from 2022-2024. Its refocus allows for resources to be placed in areas that are likely to be more profitable and allow for a competitive advantage which the ACA exchange did not allow for. -states have different rules, -80% of premiums had to go towards care, -thin profit margins due to High Medical Loss Ratios of 87%, -Low Enrollment Since late 2024 CVS has made strong strides trending up. Q1 2025 earnings were good as well with net income totaling $1.8 Billion. Couple this with recent rise in healthcare stocks thanks to news that Warren Buffet of Berkshire Hathaway purchased 5 Million shares of NYSE:UNH With all things being constant in current market conditions NYSE:CVS can rise further in a wave 1 up breaking out of this two year wave 2 down.
NYSE:CVSLong
by UCHE9121
HCA Healthcare | HCA | Long at $299.00NYSE:HCA Healthcare: P/E of 13x, earnings are forecast to grow 6.01% per year; earnings have grown 10.6% per year over the past 5 years, and trading at good value compared to peers and industry. From a technical analysis perspective, it dipped to my selected historical simple moving average area and may represent a buying opportunity to fill the daily price gap up to $394.00. Thus, NYSE:HCA is in a personal buy zone at $299.00. Target #1 = $324.00 Target #2 = $362.00 Target #3 = $394.00
NYSE:HCALong
by WorthlessViews
LLY - Clean LevelsBull flag patten on the LLY weekly Chart. The base of the flag/channel has been reactive so far although with low volume (See previously boxed LLY chart) off the top of the recent boxed range. If you look at the previous chart, you will see that LLY is currently floating up through a low volume node on the anchored volume profile. Unless sellers step in here, 708.49/709 - 711.44 is the next target. Volume will be in that area, if buyers step in, could be great for calls. Otherwise we could see a look above and fail of the top boxed range(again see previous chart under related publications to the right of this post). ~The Villain
NYSE:LLY
by The_Villain_777
Evolent Health | EVH | Long at $9.45While 2025 is expected, and has been, a bad year for Evolent Heath NYSE:EVH , the growth prospects look very, very promising. However, I will caution that the price could almost be cut in half from its current trading value ($9.45) with another poor earnings in 2025. This definitely isn't an "it's only up from here" stock. The price entered my "crash" simple moving area (green lines) twice and a third time could occur before the end of the year ($4-$5 range as of this writeup). Regardless of bottom predictions, earnings for NYSE:EVH are expected to rise from $1.9 billion in 2025 to $3.2 billion in 2028. EPS predicted to rise from $0.26 in 2025 to $1.18 in 2028. Debt-to-equity = 1.2x (okay, below 1 is best), Quick Ratio, or the ability to pays current bills is = 1x (okay, between 1.5 and 3 is best), and bankruptcy risk is relatively high (but reduced interest rates may help). Insiders have purchased over $11 million in shares this year with a cost average (~$23): much higher than it's current trading price. So, while it seems there could be some short-term risks for Evolent Health, the future beyond 2025 is bright (based on company projections). Thus, at $9.45, NYSE:EVH is in a personal buy zone with potential downside risk near $4-5 in the near-term. Targets into 2028: $15.00 (+58.7%) $20.00 (+111.6%)
NYSE:EVHLong
by WorthlessViews
Figs Inc | FIGS | Long at $5.24Figs Inc $NYSE:FIGS. Technical analysis play first, fundamentals second. My selected historical simple moving average lines have converged with the stock price, which often leads to sideways trading and a reversal in the downward trend (i.e. future price increase). The downward trend is flattening, but that doesn't mean post-earnings drop to $1.50-$2.00 isn't out of the question... The FIGS brand is growing within the healthcare world with significant opportunities overseas. While economic headwinds may impede near/medium-term growth, revenue is anticipated to grow into 2027. EPS is expected to rise from 0.01 in 2024 to 0.20 by 2027. While this is not a "value" play and there is high risk for rug pulls, something may be brewing within the chart for a move up. Tread lightly, however... Targets $6.00 $6.40 $7.00 $8.00
NYSE:FIGSLong
by WorthlessViews
Agilon Health (Revised) | AGL | Long at $0.76This is a revised analysis of Agilon Health NYSE:AGL as seen here: ------- Full disclosure: I am a holder of shares at $2.36, $0.76, and $0.79. Last entry planned near $0.50 if it reaches that level. Current cost average is near $1.11. Let me be clear: This is a ***highly risky*** trade given the recent news regarding the CEO, securities fraud investigation, suspension of FY guidance. Do your own due diligence. ------- The link above/previous writeup details some of the basic fundamentals of Agilon Health NYSE:AGL . As predicted, the price fell below $1 after the most recent earnings call. This was due to: Revenue down 6% to $1.4B, Medicare Advantage membership at 498,000. CEO Steve Sell resigning, Ron Williams appointed Executive Chairman. 2025 guidance suspended due to market challenges. New securities fraud investigations. I think the challenges NYSE:AGL is going through will extend through 2025 in into early 2026. If you look at the healthcare sector, it has taken a beating mostly due to Medicare and Medicaid cuts / rising healthcare costs. NYSE:AGL is not profitable and wasn't expected to become profitable until 2028 - but that may get revised.... However, the company focuses on senior patients, primarily through Medicare Advantage and ACO REACH programs, targeting value-based care for older adults across 31+ communities in 12 states. The need for services targeting the Baby Boom population is going to rapidly increase in the next few years. NYSE:AGL may become a leader in this area, but the company needs to regroup and focus on a model that returns money to investors - a dirty game. So, while the near-term is doom and gloom, the future could be very, very bright with NYSE:AGL if they are able to turn things around with this new leadership shakeup. Time will tell. It's a gamble. One I am, personally, willing to take. Revised Targets into 2028: $1.60 (+110.5%) $3.00 (+294.7%)
NYSE:AGLLong
by WorthlessViews
1
GE Healthcare Technology | GEHC | Long at $62.25GE Healthcare Technology $NASDAQ:GEHC. An aging and unhealthy population will only create an increased need for healthcare imaging services. Add AI to the diagnostic mix, and imaging will be imperative for routine health maintenance and screening. With a P/E of 15x, debt-to equity of 1x, earnings forecast growth of 8.36% per year, and bullish analyst ratings, this could be a good value play for the patient. Thus, at $62.25, NASDAQ:GEHC is in a personal buy zone. Further drops are possible if trade wars make imaging materials/technology difficult to obtain, but that general statement applies to the whole market at this time... Targets: $70.00 $78.00
NASDAQ:GEHCLong
by WorthlessViews
CNC EARNINGS TRADE IDEA – JULY 25, 2025 ⚠️ CNC EARNINGS TRADE IDEA – JULY 25, 2025 ⚠️ 💊 Healthcare Pressure + Missed Guidance = Bearish Setup for AMC ⸻ 📉 Sentiment Snapshot: • 🚨 Last quarter: Broke 100% beat streak • 📉 Thin margins + rising medical costs • 💬 Analyst bias: Neutral to Negative • 🧮 Fundamentals Score: 4/10 ⸻ 📊 Technical Breakdown: • 📍 Price: $26.76 (below 50DMA of $48.12) • 📉 RSI: 32.4 = Oversold but still trending down • 🛑 Testing 52W Low @ $26.25 • 🔻 Volume = 2.67x Avg → Heavy Distribution ⸻ 🧠 Options Flow Insight: • 🛡️ Heavy institutional put activity @ $28 • ⚠️ Weak call interest = bearish skew • 📉 IV crush possible post-earnings • Options Score: 6/10 ⸻ 🧬 MACRO CONTEXT: • Rising sector costs crushing providers • VIX < 15 = complacent market, sharp reactions possible ⸻ ✅ TRADE IDEA: 🎯 CNC $28 PUT (0DTE) 💵 Entry: $0.20 🎯 Profit Target: $0.60 (3x 💥) 🛑 Stop Loss: $0.10 📅 Expiry: Today (July 25, 2025) 📈 Confidence: 70% ⏰ Entry Timing: Before earnings (AMC) 📆 Close trade within 2 hours post-earnings ⸻ 📍 RISK REMINDER: • Theta decay will be brutal if flat • Watch for volatility and potential IV crush • Ideal exit zone = stock retests $26 support ⸻ 💡 Weak guide = collapse risk. 👍 Like & repost if you’re tracking CNC puts tonight! #CNC #EarningsPlay #PutOptions #HealthcareStocks #OptionsTrading #0DTE #EarningsTrade #TradingView #SPX #GammaRisk
NYSE:CNCShort
by quantsignals
HCA EARNINGS TRADE (07/24) 🚨 HCA EARNINGS TRADE (07/24) 🚨 🏥 Healthcare with earnings tonight after close — high-upside setup brewing. 🧠 Quick Breakdown: • 📊 Revenue Growth: +5.7% (stable, defensive sector) • 💸 Margins: Operating 15.6%, EBITDA 19.9% = efficient and strong • 🧠 Beat Rate: 75% with 6.7% avg surprise → credible upside • 📉 RSI: 22.5 → OVERSOLD and primed for bounce • 💬 Whisper sentiment strong from sector peers (e.g., Tenet) • 🔥 Analysts target: $391.54 → 13.8% upside 💥 TRADE SETUP 🟢 Buy HCA $375 Call exp 8/15 💰 Entry: $3.90 🎯 Target: $11.70 (200–300%) 🛑 Stop: $1.95 📈 Confidence: 73% ⏰ Entry: Before Close Today (Pre-Earnings) 📆 Earnings: Today After Market (AMC) 📊 IV Rank: 0.60 → fair pricing 📉 Expected Move: ~5% ⚠️ RSI this low + sector strength = earnings bounce candidate. Watch the $375 breakout zone. 🎯 #HCA #EarningsPlay #OptionsTrading #HealthcareStocks #UnusualOptionsActivity #CallOptions #TradingView #DayTrading #OversoldBounce #EarningsSeason
NYSE:HCALong
by quantsignals
GoHealth | GOCO | Long at $6.05GoHealth NASDAQ:GOCO is a health insurance marketplace and Medicare-focused digital health company that uses a technology platform with machine-learning algorithms to match consumers with Medicare plans (Advantage, Supplement, Part D) and individual health insurance. Understandably, a lot of investors aren't bullish on this stock given all of the healthcare provider and services headwinds. However, if the company can overcome some of their financial issues and bankruptcy risk (debt-to-equity: 1.6x; quick ration of 1.1x, Altman's Z score of .3x), it may dominate the health insurance marketplace (but do not hold my word to that...). This is a purely speculative play at this point - those who are risk averse should absolutely stay away. What truly caught my eye with this stock is that it is consolidating nicely within my historical simple moving average area. Often, but not always, this leads to a future change in momentum and propels the stock higher. It doesn't signal a bottom and there may be more room for it to plummet, but it is a bullish (overall) sign that shares are likely being accumulated by investors. Given the need for health insurance, particularly Medicare as the US / baby boom population ages, this is a company that may prosper IF it can get its financials in order. Thus, at $6.05, NASDAQ:GOCO is in a personal buy zone (but very risky). Further declines may be ahead before a stronger move up. Targets into 2028: $10.00 (+64.5%) $12.00 (+97.4%)
NASDAQ:GOCOLong
by WorthlessViews
Molina Healthcare | MOH | Long at $181.69Healthcare providers and services are at a major discount right now: and may be discounted even more this year. I am personally buying and long-term holding the fear, knowing the baby boom generation is going to utilize our healthcare system at a rate unseen in modern times. While the price discounts are valid "right now" given the current political administration's cuts, long-term it is far from valid... The strategy I am using with healthcare stocks ( NYSE:MOH , NYSE:CNC , NYSE:UNH , NYSE:ELV , etc) is cost averaging: not buying one single large position in an effort to predict bottom but buying smaller positions over time to create a cost average "near" bottom. If you are a day trader or want a quick swing in healthcare, I don't think it's going to happen for a bit. But those not entering in the coming months / year will likely miss out on a very large healthcare boom - especially when AI truly enters the picture in this sector... Fundamentally, Molina Healthcare NYSE:MOH is a very strong company. Low debt-to-equity (.9x), P/E of 8.8x, quick ratio of 1.7x, $41 billion in revenue in 2024. Yes, there will be issues in the near-term due to Medicaid and other funding cuts. But long-term, this sector is primed to benefit from an aging population. So, while NYSE:MOH is in a personal buy zone at $181.69, I don't think this is necessarily bottom. I anticipate this stock to drop even further, eventually closing the daily price gap at $135.00. My next buys are in the $150's and $130's, thus cost averaging into a larger position. For true value investors, those prices and anything below is a steal. Today's negative healthcare sector noise is loud, but it does not represent the future. Targets into 2028: $226.00 (+24.3%) $290.00 (+59.6%)
NYSE:MOHLong
by WorthlessViews
Elevance Health | ELV | Long at $286.00What are seeing in the healthcare and health insurance provider industry right now is destruction before a once-in-a-lifetime boom. The baby boomer generation is between 60 and 79 right now and the amount of healthcare service that will be needed to serve that population is staggering. Institutions are crushing them to get in - it's just near-term noise, in my opinion. My personal strategy is buy and hold every healthcare opportunity (i.e. NYSE:CNC , NYSE:UNH , NYSE:HUM etc). Elevance Health NYSE:ELV just dropped heavily due to lower-than-expected Q2 2025 earnings, a cut in full-year profit guidance from $34.15-$34.85 to ~$30 EPS, and elevated medical costs in Medicaid and ACA plans. It's near-term pain (may last 1-2 years) which will highly likely lead to long-term growth. The price has touched my historical simple moving average "crash" band. I would not be shocked to see the price drop further into the $260s before a rise. However, the near-term doom could go further into the year. I am anticipating another drop to the "major crash" simple moving average band into the $190s and $220s to close out the remaining price gaps on the daily chart that occurred during the COVID crash. Not to say it will absolutely reach that area, but it's locations on the chart I have for additional buys. Thus, at $286.00, NYSE:ELV is in a personal buy zone (starter position) with more opportunities to gather shares likely near $260 before a bounce. However, if the market or healthcare industry really turns, additional buys planned for $245 and $212 for a long-term hold. Targets into 2028: $335.00 (+17.1%) $386.00 (+35.0%)
NYSE:ELVLong
by WorthlessViews
Agilon Health | AGL | Long at $2.36Reentering this trade (original: ) Agilon Health NYSE:AGL Pros: Revenue consistently grew from 2019 ($794 million) to 2024 ($6.06 billion). Expected to reach $9.16 billion by 2028. Current debt-to-equity ratio 0.07 (very low) Sufficient cash reserves to fund operations and strategic initiatives Strong membership growth (659,000 in 2024, a 38% year-over-year increase) Recent insider buying ($2 - $3) and awarding of options Cons: Rising medical costs - currently unprofitable and not forecast to become profitable over the next 3 years Medicare Advantage Membership issues with the new political administration No dividend It's a gamble and I think it's a possibility this could drop near $1 in the near-term due to the Medicaid changes/fear... regardless, long-term, personal buy-zone at $2.36. Targets in 2027 $3.70 (+56.8%) $5.25 (+122.5%)
NYSE:AGLLong
by WorthlessViews
2
Centene Corp | CNC | Long at $35.00Centene Corp NYSE:CNC is a healthcare enterprise providing programs and services to under-insured and uninsured families, commercial organizations, and military families in the U.S. through Medicaid, Medicare, Commercial, and other segments. The stock dropped almost 40% this morning due to recent challenges, such as a $1.8B reduction in 2025 risk adjustment revenue and rising Medicaid costs (leading to withdrawal of 2025 earnings guidance). However, the company has a book value near $56, debt-to-equity of 0.7x (healthy), a current P/E of 5x, and a forward P/E of 9x. It may be a few years before this stock recovers. But the price has entered my "crash" simple moving average area (currently between $32 and $36) and there is a price gap on the daily chart between $32 and $33 that will likely be closed before a move higher. Long-term, and potentially a new political administration, new life may enter this stock once again as the baby boom generation requires more healthcare services. But holding is not for the faint of heart... Thus, at $35.00, NYSE:CNC is in a personal buy zone with a likely continued dip into the low $30s or high $20s before a slow move higher (where I will be accumulating more shares). Full disclosure: I am also a position holder in the $60s and cost averaging down. Targets into 2028: $45.00 (+28.6%) $54.00 (+54.3%)
NYSE:CNCLong
by WorthlessViews
Oscar (OSCR) – Tech-Enabled Healthcare with Margin Momentum Company Snapshot: Oscar NYSE:OSCR Health is a technology-focused health insurer leveraging data and digital platforms to deliver affordable, personalized care. Its platform-centric model improves member experience, cost control, and care outcomes—setting it apart in a highly regulated sector. Key Catalysts: Steady Execution Under Proven Leadership 🧠 CEO Mark Bertolini (ex-Aetna) brings credibility and strategic clarity, reinforcing investor trust in Oscar’s long-term viability. Focus remains on operational discipline, risk management, and scalable infrastructure. 2025 Guidance Reaffirmed 📊 Following a solid quarter, Oscar reaffirmed full-year 2025 guidance, projecting margin expansion and sustained growth despite sector headwinds. Medical loss ratio (MLR) held steady at 75.4%, absorbing a $31M prior-period hit—showing resilience in cost containment. Robust Financial Flexibility 💰 With $1B+ in free cash flow, Oscar is well-positioned for: Organic growth in new markets Potential share buybacks or dividends Continued investment in digital infrastructure Investment Outlook: Bullish Entry Zone: Above $17.00–$17.50 Upside Target: $32.00–$33.00, supported by margin stability, capital strength, and smart execution. 🩺 Oscar is transforming health insurance from reactive to predictive—backed by tech, discipline, and capital strength. #OscarHealth #OSCR #HealthTech #InsurTech #DigitalHealth #MarkBertolini #MedicalLossRatio #FreeCashFlow #TechEnabledCare #HealthcareStocks #Bullish #ValueDelivery #HealthInnovation
NYSE:OSCRLong
by Richtv_official
KALH Upside Potential?Looking purely off of KALV with the range that it has been in and the healthcare sector that it is a part of. IF healthcare sector will continue to rebound, this stock could potentially rebound as well back to the $13-$15 range. It is currently sitting right below the 200 day moving average and seems to be holding support there. I'm considering a stop loss just below $11 since this stock can move $0.83 a day with a trailing stop loss of 9%. I see it is valued under pressure of the VWAP that is currently at $12.20. This could be a beautiful continuation of the long trend that it has been in since January 2025 with an entry on this pullback. RSI looks like it is exhausting out with oversold conditions at 37.30. I like the inverted hammer that was placed and the fact that we have 3 days worth of support on the 200 day moving average. On the fundamentals, this company is a cash king in the fact they have more cash than debt. Market Cap 567.26M vs. Enterprise Value 420.76M and Insider ownership is key: Insider Ownership: 22.58%. All of which show that management are in charge and have a vision. As always, do your own research and due diligence. Not trading advice.
NASDAQ:KALVLong
by GlennTrading
eHealth | EHTH | Long at $4.22eHealth NASDAQ:EHTH , the largest online private health insurance marketplace, may be undervalued. The book value is listed around $19 a share and it has a debt-to-equity of 0.07x (healthy), a quick ratio of 2.5 (strong liquidity, can cover liabilities), growing revenue since 2021 (over $500M in 2024), and insiders have recently bought shares/awarded options. However, profitability is still a concern, but the company is expected to be profitable by 2026. With the US's aging population and the need for affordable healthcare coverage, eHealth *may* standout as a major insurance marketplace... but time will tell. From a technical analysis perspective, the stock price is near the bottom of its historical simple moving average. I do not doubt, however, that the stock may slip to cover the small price gap between $3.09 and $3.23 (which will be another entry point if fundamentals do not change). This stock may trade sideways for some time. But it has a 27M float and as we saw in 2014 and 2020, it can REALLY get going if buyers see the opportunity... Thus, at $4.22, NASDAQ:EHTH is in a personal buy zone with more opportunity potentially near $3 in the future. Targets: $6.00 (+42.2%) $8.00 (+89.6%)
NASDAQ:EHTHLong
by WorthlessViews
UnitedHealth Group | UNH | Long at $323.00UnitedHealth Group NYSE:UNH currently has a P/E near 15x, steady rising revenue (2024 = $400+ billion), EPS of 6.24x, dividend of 2.2%, and earnings are forecast to grow by 10.8% per year. The stock, however, has plummeted recently due to negative news, rising healthcare costs, CEO changes, and suspension of 2025 outlook. Every company has bumps, but I view solid companies like NYSE:UNH as pure opportunities for long-term investment - especially with America's aging population. From a technical analysis perspective, the stock price has entered my "crash" simple moving average zone (which currently extends down near $307.00). Personally, this is the zone I am starting a position due to the odds of a future bounce from here. However, I am very aware that there is an open price gap near $265.00 that may get filled this year or early next. I could see a bounce in my crash zone to bring in the bulls and then a drop to that level to heighten the fear. That is another area I plan to grab more shares and build a strong position. But, in case it doesn't extend that low, I have started a position at $223.00, with future investments near $307.00 and below. I doubt this will be a quick turnaround stock - patience is where money is made. Targets (into 2028): $375.00 $475.00 $580.00
NYSE:UNHLong
by WorthlessViews
Acadia Healthcare Company | ACHC | Long at $21.98Acadia Healthcare's NASDAQ:ACHC stock has fallen nearly -76% in a year, primarily due to weak 2024 results, missed revenue and EPS expectations, and a soft 2025 revenue guidance. Ongoing federal investigations into billing practices and lawsuits have further eroded investor confidence. However, it is currently trading at a price-to-earnings ratio of 7.42x and earnings are forecast to grow 7.07% per year. The profitable company is trading at a good value compared to other healthcare companies. Debt-to-equity is relatively low (0.64x), but legal risks (DOJ probe, lawsuits) strain margins. The stock has entered my "major crash" simple moving average territory and there is a lot of downward / selling pressure. But, more often than not, this area (which... I caution... still extends down near $16) can often signal a temporary or longer-term bottom. Personally, this is a buy area ($16-$21) even if it turns into a short-term bounce in 2025. But I believe the overall market moves in the S&P 500, etc. will guide this stock more than anything at this point (unless more bad news about the company emerges). One thing to note is that there are open price gaps on the daily chart near $17, $10, and $8. These gaps, which often (but not always) get closed in the lifetime of a stock, are a potential signal for further declines - at least at some point. There could be a drop near $16, then a $10-$20 bullish price increase after that, followed by more declines (trapping investors). Time will tell, but NASDAQ:ACHC is currently attractively valued. From a technical analysis standpoint, it is in a personal "buy zone", even if purely for a swing trade. Targets: $27.00 $33.00 $39.00
NASDAQ:ACHCLong
by WorthlessViews